



JAK inhibitors

| Discovery | Cat.No. | Product Name | Information | | | | | Selectivity | Clinical Trial |
|-----------|---------|--|-----------------------|--------------------------|-------------|--------------|---------------------------------|-------------|----------------|
| 2010 | S1378 | Ruxolitinib (INCB018424) | IC ₅₀ (nM) | JAK1 3.3 | JAK2 2.8 | JAK3 428 | Others Tyk2 | | Phase 2 |
| 2010 | S5001 | Tofacitinib Citrate <i>Licensed by Pfizer</i> | IC ₅₀ (nM) | JAK3 1 | JAK2 20 | JAK1 112 | | JAK3 | Phase 4 |
| 2008 | S2736 | TG101348 (SAR302503) | IC ₅₀ (nM) | JAK2 3 | | | | JAK2 | Phase 3 |
| 2011 | S2162 | AZD1480 | IC ₅₀ (nM) | JAK2 0.26 | JAK1 1.3 | | | | Phase 1/2 |
| 2003 | S2789 | Tofacitinib <i>Licensed by Pfizer</i> | IC ₅₀ (nM) | JAK3 1 | JAK2 20 | JAK1 112 | | JAK3 | Phase 4 |
| 2010 | S2851 | Baricitinib (LY3009104, INCB028050) | IC ₅₀ (nM) | JAK1 5.9 | JAK2 5.7 | JAK3 >400 | Others Tyk2 | | Phase 3 |
| 2008 | S2796 | WP1066 | IC ₅₀ (μM) | JAK2 (HEL cells) 2.30 | | | Others STAT3/5,ERK1/2 | | Phase 1 |
| 2009 | S1134 | AT9283 | IC ₅₀ (nM) | JAK2 1.2 | JAK3 1.1 | | Others Aurora A/B,Abl(T315I) | | Phase 2 |
| 2009 | S2219 | CYT387 | IC ₅₀ (nM) | JAK1 11 | JAK2 18 | JAK3 155 | | | Phase 3 |
| 2008 | S2214 | AZ 960 | IC ₅₀ (nM) | JAK2 <3 | JAK3 9 | | | | Phase 3 |
| 2004 | S8004 | ZM 39923 HCl NEW | pIC ₅₀ | JAK1 4.4 | JAK3 7.1 | | Others EGFR,TGM2 | | |